News

MCLEAN, VA & JAKARTA, INDONESIA — May16, 2025 — Perthera, The Therapeutic  Intelligence Company, and PathGen Diagnostik Teknologi, Indonesia’s premier molecular diagnostics provider, have announced a strategic partnership to democratize access to high quality cancer care across Indonesia. By combining Perthera’s AI-driven treatment intelligence with PathGen’s extensive local infrastructure and clinical expertise, the collaboration aims to integrate molecular profiling, bioinformatics, and evidence-based decision support into  Indonesia’s oncology treatment landscape, significantly improving patient outcomes while  reducing healthcare costs.  Partnership Overview “At Perthera, we are dedicated to transforming cancer care through our AI-powered Precision Oncology Platform that precisely matches cancer patients with therapeutic treatment options  specific to […]

Findings published in The Oncologist underscore the need to account for metastatic site and genomic context in pancreatic cancer trial design MCCLEAN, VA, UNITED STATES, March 31, 2025 — In a significant advancement for pancreatic cancer research, Perthera announces a new peer-reviewed study published in The Oncologist highlights the critical impact of metastatic site on patient survival — with major implications for drug development and clinical trial design. Conducted by a cross-institutional team led by Cedars-Sinai Medical Center and powered by Perthera’s real-world data, the study found that patients with lung metastases from Pancreatic Ductal Adenocarcinoma (PDAC) live significantly longer […]

First-of-Its-Kind AI Predictor Eliminates Guesswork in Frontline Chemotherapy Selection, Empowering Oncologists with Unprecedented Data-Driven Insights MCCLEAN, VA, UNITED STATES, February 26, 2025 — Perthera, The Therapeutic Intelligence Company, today announced the launch of the Perthera Report® Pancreatic version (PRPv)—a game-changing precision oncology tool designed to revolutionize pancreatic cancer treatment for newly diagnosed patients with metastatic cancer being treated at frontline. This new version of the Perthera Report was designed specifically for oncologists treating pancreatic cancer patients and includes Perthera’s recently announced frontline chemotherapy predictor. Perthera’s ranked therapy report uniquely uses a patient’s prior medical history and molecular test results to precisely rank […]

MCCLEAN, VA, UNITED STATES, January 23, 2025 — Perthera, a leader in precision oncology, will present follow-on research and validation of the world’s first AI-driven chemo predictor for frontline treatment in pancreatic cancer (PDAC) at the 2025 ASCO Gastrointestinal Cancers Symposium. This groundbreaking advancement, PDACai, was first discussed at ASCO 2023 and has since undergone significant advancements and extensive validation efforts. The announcement of this breakthrough in the frontline treatment of pancreatic cancer was made on January 14, 2025. Perthera will be making this predictor available to ordering physicians and their patients as part of the Perthera Report Pancreatic Version (PV) in […]

MCCLEAN, VA, UNITED STATES, December 19, 2024 — Perthera, a leader in AI-driven precision oncology, announces the release of version 4.0 of The Perthera Report®, an innovative decision-support tool that helps oncologists synthesize vast amounts of data to identify the optimal therapy for patients. By transforming complex molecular and multi-omic data into ranked, actionable therapy options, The Perthera Report saves time, reduces complexity, and improves patient outcomes. Addressing the Growing Complexity of Cancer Care The Perthera Report 4.0 tackles the challenges oncologists face today, including the rapid expansion of biomarkers, therapies, and clinical trials, which has made interpreting molecular diagnostic […]